文献速递生殖医学妇科

短期睾酮暴露不损害雌鼠卵母细胞受精能力:对跨性别男性生育照护的启示

Short-term testosterone use in female mice does not impair fertilizability of eggs: implications for the fertility care of transgender males.
PubMed 文献 · Hum Reprod · 2021-01-01

研究用66只青春期后雌性小鼠,每周皮下注射400 µg睾酮或芝麻油共6周,评估卵巢反应和卵母细胞受精能力。结果显示睾酮引起男性化和卵巢变小,但超促排卵后仍能产生与对照相似数量且可受精并卵裂的卵子。提示睾酮抑制的卵巢可能仍对促性腺激素有反应,或无需在促排卵前停用睾酮。

要点

  • 睾酮处理使雌鼠睾酮升至雄鼠水平并停止动情周期。
  • 睾酮组卵巢显著变小但卵泡 cohorts 正常,促排卵后获卵数与对照相似。
  • 获卵可体外受精并卵裂,提示短期睾酮不损害受精能力。

核心结论

  • 短期睾酮暴露的雌鼠卵巢虽变小但仍对促性腺激素有反应,可产生并排出可受精的卵子。

研究设计与样本

  • 66只6周龄Hsd:NSA(CF-1)雌鼠和6只Hsd:ICR(CD-1)雄鼠,每周皮下注射400 µg睾酮或芝麻油共6周,分活跃暴露组和洗脱组。

主要发现

  • 睾酮组睾酮水平升至雄鼠水平并停止动情周期。
  • 睾酮组卵巢显著小于对照,但含正常卵泡 cohorts。
  • 促性腺激素刺激后排卵数与对照相似,且卵子可体外受精并卵裂至二细胞期。

关键数值与推荐

  • 睾酮剂量为每周皮下注射400 µg,持续6周。
  • 活跃暴露组于末次注射后1周处死,洗脱组于末次注射后6-7周处死。

临床怎么用

  • 当前跨性别男性生育照护常规是促排卵前停用睾酮,但本研究提示短期暴露后卵巢仍可反应。
  • 结果可能为未来跨性别男性生育治疗临床试验提供参考,但尚不能直接改变临床实践。

局限性

  • 小鼠仅治疗6周,而跨性别男性常使用睾酮多年。
  • 未评估发育潜能。
  • 小鼠模型可能不能完全模拟人类生殖生理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does testosterone use in females affect reproductive potential, particularly with regard to the production of fertilizable gametes? SUMMARY ANSWER: Testosterone (T) injections given to post-pubertal female mice caused virilization and although the ovaries were smaller than controls they were still responsive and produced fertilizable eggs when superovulated. WHAT IS KNOWN ALREADY: Studies to examine the effects of testosterone on reproductive potential in transgender males are lacking. Recently, a model was developed that simulates many aspects of testosterone use in transgender males in order to look at reproductive effects of testosterone in female mice. This study found masculinizing effects on the mice but did not find significant deficits on the number of ovarian follicles; however, effects of testosterone use on ovarian stimulation and fertilizability of oocytes were not investigated. STUDY DESIGN, SIZE, DURATION: A total of 66, 6-week-old Hsd:NSA (CF-1) female mice and six Hsd:ICR (CD-1) male mice were used for this study. Mice were injected s.c. with 400 µg T or sesame oil once a week for 6 weeks and were either killed 1 week after the sixth injection (active exposure group), or 6-7 weeks after the final T injection (washout group). PARTICIPANTS/MATERIALS, SETTING, METHODS: Both active exposure and washout groups were further subdivided into three groups: unstimulated, equine CG (eCG)-stimulated or eCG/hCG-stimulated. eCG-stimulated mice were killed 44-48 h after eCG injection. eCG/hCG-stimulated mice were injected with eCG, followed 48 h later with hCG. Mice were killed ∼13-18 h after the hCG injection. Data collected included daily vaginal cytology, terminal testosterone levels, ovary weights and histology, number of oocytes/eggs collected in each group, and cleavage to the two-cell stage following IVF. MAIN RESULTS AND THE ROLE OF CHANCE: Testosterone-treated mice had testosterone levels elevated to the level of male mice and ceased cycling. Ovaries were significantly smaller in testosterone-treated mice, but they contained normal cohorts of follicles and responded to gonadotrophin stimulation by ovulating similar numbers of eggs as controls, that fertilized and cleaved in vitro. LIMITATIONS, REASONS FOR CAUTION: Mice were treated for only 6 weeks, whereas many transgender men use testosterone for many years before considering biological children, and developmental competence was not assessed. Importantly, a mouse system may not perfectly simulate human reproductive physiology. WIDER IMPLICATIONS OF THE FINDINGS: The current standard of care for transgender men who desire biological children is to cease testosterone therapy prior to ovarian stimulation, but the necessity for stopping testosterone is not known. Our model demonstrates that it is possible for testosterone-suppressed ovaries to respond to gonadotrophic stimulation by producing and ovulating fertilizable eggs, thereby obviating the need for testosterone cessation prior to ovarian stimulation. In time, these results may provide insights for future clinical trials of fertility treatment options for transgender men. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Reproductive Endocrinology and Infertility fellowship program through UConn Health Graduate Medical Education (to C.B.B.). The authors have no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Bartels CB, Uliasz TF, Lestz L, et al. Short-term testosterone use in female mice does not impair fertilizability of eggs: implications for the fertility care of transgender males. Hum Reprod. 2021. PMID: 33160287. doi:10.1093/humrep/deaa282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。